Sugi Predict

Sugi Predict / Targets / NEU3

NEU3

Sialidase-3 · Q9UQ49 · NEU3 on Sugi Atlas →

4,224 patent compounds predicted against NEU3, 2,150 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7826508 SCHEMBL7826508 0.57 11/20
SCHEMBL7826509 SCHEMBL7826509 0.57 11/20
SCHEMBL6018101 SCHEMBL6018101 0.67 10/20
SCHEMBL7825766 SCHEMBL7825766 0.56 10/20
SCHEMBL7825775 SCHEMBL7825775 0.56 10/20
SCHEMBL6018122 SCHEMBL6018122 0.79 9/20
SCHEMBL6018926 SCHEMBL6018926 0.71 9/20
SCHEMBL6017862 SCHEMBL6017862 0.61 9/20
SCHEMBL6017850 SCHEMBL6017850 0.60 9/20
SCHEMBL6018295 SCHEMBL6018295 1.00 8/20
SCHEMBL6017871 SCHEMBL6017871 0.96 8/20
SCHEMBL6018299 SCHEMBL6018299 0.91 8/20
SCHEMBL6018255 SCHEMBL6018255 0.79 8/20
SCHEMBL6018006 SCHEMBL6018006 0.79 8/20
SCHEMBL6018018 SCHEMBL6018018 0.78 8/20
SCHEMBL6018907 SCHEMBL6018907 0.78 8/20
SCHEMBL6019140 SCHEMBL6019140 0.75 8/20
SCHEMBL7117750 SCHEMBL7117750 0.75 8/20
SCHEMBL7117753 SCHEMBL7117753 0.75 8/20
SCHEMBL6018090 SCHEMBL6018090 0.74 8/20

Clinical trials — most relevant to NEU3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19 PHASE4UNKNOWN
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia PHASE1/PHASE2RECRUITING
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML PHASE1/PHASE2NOT_YET_RECRUITING
A Study of Monosialic Gangliosides to Prevent Albumin-bound Paclitaxel Neurotoxicity PHASE2COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases PHASE1COMPLETED
Universal CAR-T Cells Targeting AML PHASE1RECRUITING
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies EARLY_PHASE1UNKNOWN
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies EARLY_PHASE1UNKNOWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
The Natural History of Sialidosis Type I nanRECRUITING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
Registry Gangliosidoses nanUNKNOWN
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency nanCOMPLETED
A Natural History Study of Patients With GNE Myopathy and GNE-Related Diseases nanCOMPLETED
Early Detection and Follow-Up of Patients With Fabry's Disease nanUNKNOWN
Proteomics & Glyco-Proteomic Analysis of Follicular Fluid nanUNKNOWN
Histoblood Group Antigens as a Risk Factor of Asthma nanCOMPLETED
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain nanCOMPLETED
Biomarker for Farber Disease (BioFarber) nanWITHDRAWN
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes nanCOMPLETED
Canadian Fabry Disease Initiative (CFDI) National Registry nanRECRUITING
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN
Mucin Glycosylating Enzymes in Head and Neck Cancers nanUNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING
COVID-19 Coagulopathy Extension Study nanRECRUITING
sCD163 in HELLP Syndrome nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NEU3 binder may also engage these)

ProteinNameSimilarity
Q9JMH7 — 1.000 Q9JMH7 →
O97859 — 0.999 O97859 →
Q99PW5 — 0.996 Q99PW5 →
Q8BZL1 — 0.992 Q8BZL1 →
Q9JMH3 — 0.989 Q9JMH3 →
Q64627 — 0.983 Q64627 →
Q64393 — 0.978 Q64393 →
NEU4 Sialidase-4 0.973 landscape →
NEU2 Sialidase-2 0.972 landscape →
Q865R1 — 0.970 Q865R1 →
Q5XIA3 — 0.967 Q5XIA3 →
Q8BZW8 — 0.967 Q8BZW8 →
P49753 — 0.967 P49753 →
O60294 — 0.966 O60294 →
Q9BRP7 — 0.966 Q9BRP7 →
O95479 — 0.966 O95479 →
P10937 — 0.966 P10937 →
A7Z052 — 0.966 A7Z052 →
Q8QZW3 — 0.965 Q8QZW3 →
A7E3S5 — 0.965 A7E3S5 →
Q3UY23 — 0.965 Q3UY23 →
Q8BYR1 — 0.965 Q8BYR1 →
Q68DD2 — 0.965 Q68DD2 →
Q5HZW3 — 0.965 Q5HZW3 →
Q9NNW5 — 0.965 Q9NNW5 →
D4ABH7 — 0.965 D4ABH7 →
Q5R8R3 — 0.965 Q5R8R3 →
A6QQ07 — 0.964 A6QQ07 →
Q91ZJ0 — 0.964 Q91ZJ0 →
Q9JLC4 — 0.964 Q9JLC4 →